

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

Current Position

- Professor, Washington University in St. Louis, (3/2015 – present), Department of Psychiatry, Division of Child Psychiatry

Recent Position

- Associate Professor, University of Kentucky, (7/2001 – 2/2015), tenured on 7/2007
Department of Psychiatry, Pediatrics, and Anatomy & Neurobiology

Current Activities

- Physician Scientist, involved in basic, clinical, and translational studies which focus on increasing our understanding of the behavior, development, and treatment of brain disorders such as Adolescent Substance Abuse, ADHD, and Autism.
- Professor, with teaching roles in the community, classroom, and clinic.
- Director of Psychiatric Services at Preferred Family Healthcare (Adolescent Substance Abuse Treatment Centers), and Clarity (Federally Qualified Health Care Center)

Education / Training

- Residency (7/1996-6/2001) University of Kentucky
 - Triple Board Program - Pediatrics/Psychiatry/Child Psychiatry
- M.D. / Ph.D. (MSTP, 7/1986-6/1996) Washington University in St. Louis
 - Biology and Biomedical Sciences (Divisions of Biochemistry and Neuroscience)
- M.S. (7/1984-6/1986) University of Chicago Biochemistry
- B.S. (7/1982-6/1986) University of Chicago Chemistry

Medical Specialty Boarding

- 2018 – Passed – ABP – Pediatrics (Recertification Exam)
- 2014 – Passed – ABPN – Child and Adolescent & Adult Psychiatry (Recertification Exam)
- 2007 – Passed – ABP – Pediatrics (Recertification Exam)
- 2005 – Passed – ABPN – Child and Adolescent Psychiatry
- 2003 – Passed – ABPN – Adult Psychiatry
- 2000 – Passed – ABP – Pediatrics

Grants

- (7/2020-present) IDDRC Co-Director of Clinical Trials Branch for Individuals with Developmental Disorders
 - (3/2016-present) ABCD NIDA Study, collaborating with Andrew Heath, Pamela Madden, and Deana Barch
 - (9/2017-8/2020) Smoking, Suicide and Mental Health: Using Policy Change to Probe Causality, Gruzca PI
 - (9/2017-11/2018) A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-dose Safety and Efficacy Study of SPD489 Compared with Placebo in Preschool Children Aged 4-5 Years with Attention-deficit/Hyperactivity Disorder
-

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

-
- (6/2014-present) Metropolitan St. Louis Autism & Developmental Disabilities Surveillance & Epidemiology, Constantino PI
 - (7/2016-present) Missouri Autism Centers of Excellence, Constantino PI
 - (11/2015-6/2017) Epigenetics in Father Opiate Abuse, collaborating with Ted Cicero
 - (2/2013-2/2015) Medications Development for Cocaine: A Translational Approach in Monkey and Human, PI – Josh Lile, PhD
 - (12/2013-2/2015) PI, Alcobra Clinical Trial – Metadoxine ER, Adult ADHD, Phase III
 - (7/2013-12/2014) PI, Sunovion Clinical Trial – Autism Lurasidone, Phase III
 - (6/2013-6/2014) PI, Shire Clinical Trial SPD489-405 –Adol.ADHD, Phase IV
 - (7/2001-present) Co-PI collaborator with multiple grants with PI -Craig Rush PhD, William Stoops PhD, Behavioral Psychopharmacology of stimulant abuse:
 - R01 Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab Studies
 - R21 Human Laboratory Study to Investigate Buspirone for Cocaine Use Disorders
 - R01 Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence
 - R01 Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
 - R21 Motivation for Cocaine and Non-Drug Reinforcers: Targeting Glutamate Homeostasis
 - R21 Buspirone as a Candidate Medication for Methamphetamine Abuse
 - (2/2011-8/2013) PI, Lilly Clinical Trial HMGI –Child/Adol. GAD, Cymbalta, Phase III
 - (7/2009-10/2012) PI, Lilly Clinical Trial HGMX –Adolescent Schiz/Bipolar, Zyprexa, Phase IV
 - (8/2009-12/2010) PI, Lilly Clinical Trial LYEB– Adolescent ADHD/Dyslexia, Strattera, Phase III
 - (4/2004-3/2009) K08 – Career Development Award (NIMH)- ADHD, Stimulants,&D4 Knockout Mice
 - (4/2007-9/2009) Medical Collaborator – Autism Speaks, fMRI Study, PI-Jane Joseph, PhD
 - (4/2007-10/2008) PI, Lilly Clinical Trial LYDZ - Adult ADHD, Strattera, QEEG, Phase IV
 - (1/2006-10/2007) PI, Lilly Clinical Trial LYDQ - Adult ADHD/ Social Anxiety Strattera, Phase III
 - (7/2004-6/2006) COBRE Grant
 - (7/2002-6/2004) University of Kentucky Physician-Scientist Award
 - (7/2002-6/2004) NARSAD Young Investigator Award – Risperidone Metabolism
 - (7/2000-6/2002) Children’s Miracle Network Award

Awards & Recognition

- (2020) Teacher of the Year, Child Adolescent Psychiatry Program
- (2019) Featured Speaker ROCAP – Legalization of Marijuana and Teens
- (2017) Featured Speaker ROCAP - SUD in Teens
- (2016) Teacher of the Year, Child Adolescent Psychiatry Program
- (2014) NAMI – Community Speaker Award
- (2011) Outstanding Supervisor, Psychiatry
- (2010) Outstanding Research Mentor, Child Psychiatry
- (2007) Promotion to Associate Professor with Tenure
- (2006) Outstanding Poster of Meeting, In VIVO Neuroscience 2006, Sardinia, Italy
- (2005) Received Fellow Status in American Association Pediatrics (F.A.A.P.)
- (2004) Chairman’s Award for Outstanding Research in Psychiatry
- (2003) Otsuka Developmental Neuroscience and Child Psychiatry Awardee
- (2003) Adult Psychiatry Board Certified
- (2002) Travel Award – 4th Annual Future Leaders in Psychiatry Meeting
- (2001) Janssen Outstanding Psychiatry Resident Award
- (1998-2000) ACP PRITE Fellowship (Member of PRITE Editorial Board/ American College of Psychiatrists)
- (2000) Psychiatry Research Resident of the Year Award
- (2000) General Pediatrics Resident of the Year Award
- (1998) NIMH Outstanding Psychiatry Resident Award
- (1997) Genetics Resident of the Year Award

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

-
- (1996) Surgical Pathology Award
 - (1992-1994) Pharmacology Research Training Award

Memberships

- Missouri Association of Pediatrics (2015 – present)
- Missouri Regional Child and Adolescent Psychiatric Association (2015 –present)
- American Acad. of Child and Adolescent Psychiatry (2001-present)
- National Alliance on Mental Illness (NAMI) professional member (2003-present)
- Society for Neuroscience (2002 - present)
- Autism Society of America (2002-present)
- Kentucky Association of Pediatrics (2001 – 2015)
- Kentucky Psychiatric Association (1997 – 2015)
- American Association of Pediatrics (1996 – present)
- Christian Medical Association (1994 – present)

Invited Lectures

- (2023) Sheppard Pratt Grand Rounds - Teen Substance Use Trends in the Era of Legalized Marijuana - Baltimore, MD
 - (2023) Grand Rounds - Teen Use of Cannabis, THC, CBD, delta-8 THC, and Other Drugs in the Era of Legalized Medical Marijuana, Siriraj Hospital - Bangkok, Thailand
 - (2022) Grand Rounds – Missouri Teen Cannabis Use Disorder in the Era of Legalized Marijuana – Wash U St. Louis
 - (2022) Panel Discussion – Dual Diagnosis: Autism and Developmental Disorders – MOADD, Columbia, MO
 - (2022) AACAP Talk – Establishing a Teen Substance Use Clinic – Toronto, CA
 - (2022) The Teenage Brain: What Could Go Wrong? – Athens, Greece
 - (2021) Symposium Speaker/Chair – Stimulant Use Disorder in Teens –AACAP – (Zoom)
 - (2021) Grand Rounds – Towards a Neuropsychopharmacology of Teen SUD – Wash U St. Louis
 - (2020) Grand Rounds – Teen Substance Use – University of Kentucky (Zoom)
 - (2019) Grand Rounds – Adolescent Anxiety and Depression - Alton Memorial Hospital, IL
 - (2019) Teen Marijuana Abuse – Grand Rounds - Siriraj Hospital - Bangkok, Thailand
 - (2018) World Addictions - CMDE - Athens, Greece
 - (2018) Symposium on Isomers in ADHD - CHADD National Meeting
 - (2017) PCP Options for Teens with ADHD and Substance Abuse - Fall Community Pediatrics Update, Chesterfield, MO
 - (2017) Teen SUD and ADHD - Should We Use Stimulants? - Laybourn Symposium, Kansas City, KS
 - (2017) Grand Rounds Lecturer - The Neurobiology of Addiction - Siriraj Hospital - Bangkok, Thailand
 - (2016) MO Association of Pediatrics - Fall Conference. "Adolescent Drug Use: Practical Interventions" Old Kinderhook, Lake of the Ozarks, MO
 - (2015) Grand Rounds Lecturer - Treatments for Adolescents with ADHD and SUD - Siriraj Hospital - Bangkok, Thailand
 - (2015) Keynote Speaker, Bluegrass Autism Society Annual Meeting
 - (2014) CME Lectures – ADHD, Learning Disorders, Reactive Attachment Disorder – CMDE Conference, Eretria, Greece
 - (2014) NAMI Family Series "Psychiatric Medications – The Good, the Bad, and the Ugly" – Lexington, KY
 - (2013) "Depression and More: Changes in the DSM-5" – KAPA Conference, Lexington, KY
 - (2013) "Animal Models of ADHD: The Role of Glutamate" – AACAP, Orlando, FL
 - (2013) "Cardiovascular Effects of IV Cocaine in Substance Abuse" – VCU, Richmond, VA
 - (2013) "Neuropsychopharmacology of ADHD" Grand Rounds, Mahidol University, Bangkok, Thailand
 - (2013) CME Lectures – ADHD, Learning Disorders, Reactive Attachment Disorder – CMDE Conference, Chang Mai, Thailand
 - (2013) "Bipolar Affective Disorder" – Family Medicine Review, Lexington, KY
-

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

-
- (2012) "Depression and its Treatment" Kentucky Women's Group, Frankfort, KY
 - (2012) "Behavioral Problems in Toddlers" KAPA Conference, Lexington, KY
 - (2012) "Autism" Family Medicine Review, Lexington, KY
 - (2011) "Animal Models and the Co-Occurrence of Autism Spectrum Disorder and ADHD" AACAP Meeting, Toronto, CA.
 - (2011) "Teen Substance Abuse" Family Medicine Review, Lexington, KY.
 - (2011) "Implications of Brain Development on Attachment and Personality Disorders" Four Rivers Behavioral Health Symposium, Paducah, KY.
 - (2011) "Thinking of Using Adderall/Ritalin for your Finals?" UK Town Hall Meeting for Bluegrass Society of Neuroscience. Lexington, KY.
 - (2010) "Recognizing and Managing Autism Spectrum Disorders in Primary Care" Trover Symposium, Madisonville, KY.
 - (2010) "Not All Depression is MDD" Kentucky Physicians Assistant State Conference.
 - (2010) "Managing Depression and Anxiety in a Pediatric Office" Commonwealth Peds, Lexington, KY.
 - (2009) "Medical Issues of Children on Psychotropic Drugs" Kentucky Pediatric Society, Glasgow, KY.
 - (2009) "Neuropsychopharmacology of ADHD" Resident Didactics, Washington Univ. St. Louis, MO.
 - (2009) "Subsecond Glutamate Recordings in ADHD" Biochemistry Rounds, SLU, St. Louis, MO.
 - (2009) "Current Treatment and Research in ADHD" Psychiatry Grand Rounds, SLU, St. Louis, MO.
 - (2008) "Office Management of Depression and Anxiety" Kentucky Pediatric Society, Glasgow, KY.
 - (2008) "Adolescent Depression: Best Choices for Safe Treatment" Methodist Hospital, Henderson, KY.
 - (2008) "Autism Workshop: Training for Early Childhood Professionals" Louisville, KY
 - (2007) "Is ADHD a hypodopaminergic state?" Research Brown Bag, NYU, NY, NY.
 - (2007) "Medications for ADHD: Best Choices for Children, Adolescents, and Adults" Bluegrass Regional CHADD conference, Lexington, KY.
 - (2006) "Opening Pandora's Black Box, Are Treatments for Children and Adolescents With ADHD Safe?", Pediatric Grand Rounds, University of Kentucky
 - (2006) "Current Research in ADHD" Psychiatry Grand Rounds, University of Louisville
 - (2006) "Pharmaceutical Interventions for Autism Spectrum Disorders" – Bluegrass Autism Symposium, Cardinal Hill, Lexington, KY.
 - (2005) "Current Treatment for ADHD – Children and Adult" FMR, Lexington, KY.
 - (2005) "Abuse and Stimulants: Exploring Stimulant Abuse & Cigarette Smoking in a Human Lab" Research Administrative Meeting, NYU, NY, NY.
 - (2005) "Treating Child and Adolescent Depression: Are SSRIs Safe?" Kentucky Psychiatric Association – Annual Meeting, Louisville, KY.
 - (2004) "Presenting Case Studies to Physicians" – Breakout Session, Scottsdale, AZ.
 - (2004) Keynote Speaker – "ADHD – What is Current Therapy Now?" Kentucky Medical Association – Annual Meeting, Louisville, KY.
 - (2004) Special Topic Dinner – "Depression, Trauma, and Suicide in Children and Adolescents" – Lexington, KY.
 - (2004) "Expert Panel Debate – Treatment of Depression and Anxiety", Lexington, KY.
 - (2003) "Autism: Current State of Knowledge" – Family Practice Review, Lexington, KY.
 - (2003) "ADHD: Recent Insights from Neuroimaging & Neurochemistry" – Neurology Grand Rounds
 - (2003) "Atypical Antipsychotics in the Pediatric Clinic" – Contemporary Pediatrics for the Practicing Physician and Other Health Care Professionals, Lexington, KY.
 - (2003) "Current Research in ADHD: Applications for the Clinic" – 29th Annual Advances in Clinical Psychiatry and Psychopharmacology, Louisville, KY.
 - (2002) "Ants in their Pants: Risperidone Metabolism in Children and Adolescents" University of Kentucky – K30 Research Retreat
 - (2002) Psychiatry Grand Rounds – University of Kentucky: "The Neuropsychopharmacology of ADHD"
 - (2002) 15th Annual Midwest Nurse Practitioner Convention – Lexington, Kentucky: "Behavior Problems in the Preschool Child"
 - (2001) Anatomy & Neurobiology Grand Rounds – University of Kentucky: "The effect of stimulants on Dopamine Neurotransmission"
-

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

-
- (2001) Guest speaker – Bluegrass Society for Autism “Treatment of Autistic Disorder”
 - (2001) Pediatric Grand Rounds – University of Kentucky: “ The Diagnosis, Screening, and Treatment of Autistic Disorder”

Television/Media

- (Sept 2019) NBC News – School Drug Testing – Does It Help? <https://www.nbcnews.com/health/kids-health/school-districts-double-down-drug-testing-targeting-even-middle-schoolers-n1049381>
- (Fall 2016) Children’s Hospital Kids Today - Preparing for College
- (April 2015) STL Channel 5 -St. Louis expert discusses Autism and Technology - <http://www.chillicothe Gazette.com/story/news/local/2015/04/02/stl-autism-experts-discuss-technology-impact/70861498/>
- (October 2012) Character Matters “Obedience”, FCPS Channel, Lexington
- (March 2011) “Dr. Paul Glaser Answers Questions on Autism & Vaccines” WTVQ, Lexington, http://www.wkyt.com/findit/goodquestion/headlines/Good_Question_Do_vaccines_really_cause_Autism_114984419.html
- (October 7, 2008) “Curbs sought on psychiatric drugs given to children” Lexington Herald-Leader
- (April 21, 2005) “About Autism: School Interventions” – Interview Segment
- (April 14, 2005) “About Autism: Diagnosis and Early Intervention” – Panel Discussant

Teaching

- (2022-present) MOADD ECHO Hub (Missouri Statewide Hub for Autism and Dev. Disorders)
- (2017-Present) Adolescent Substance Use Rotation - CAP program
- (2014) Mentored/Graduated Ph.D. – Erin Miller – Anatomy & Neurobiology UK
- (2009-Present) Developmental Disorders Clinic – for Child Psychiatry Fellows
- (2003-Present) Lecturer in Third Year Medical Student Psychiatry Rotation
- (2001-Present) Course Director – Neuroscience Review for Psychiatrists
- (2008) Mentored/Graduated Ph.D. – Theresa C. Thomas – Anatomy & Neurobiology UK
- (2007) Psychiatric Genomics
- (2007) Advanced Child Psychopharmacology
- (2006) Mentored/Graduated Ph.D. – B. Matthew Joyce – Anatomy & Neurobiology UK
- (1996-Present) Medical Student/Resident Supervision & Lecturer
- (2001-Present) Graduate School Thesis Committees in Anat. Neurobio, Psychology, and Chemistry
- (2001-3) Advanced Psychiatry Resident Lectures “Advanced Psychopharmacology”
- (2001) Psychiatry Resident Lectures “Basic Neurobiology for Psychiatrists” – Course Coordinator
- (1996-Present) Medical Student/Resident Supervision & Lecturer

Publications

1. Dawson, G & Glaser, PE "Apparent Cathepsin B deficiency in Neuronal Ceroid Lipofuscinosis can be explained by peroxide inhibition" (1987) *Biochem. Biophys. Res. Comm.* 147,267-274.
 2. Dawson, G & Glaser, PE "Abnormal Cathepsin B activity in Batten's Disease" (1988) *Am. J. Med. Genetics* 5,209-220.
 3. Ford, DA, Miyake, R, Glaser, PE, & Gross, RW "Activation of Protein Kinase C by naturally occurring ether-linked diglycerides." (1988) *J. Biol. Chem.* 264, 13818-13824.
-

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

-
4. Glaser, PE & Gross, RW " Plasmylethanolamine facilitates membrane fusion: A stopped flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt a HII phase with its ability to promote membrane fusion." (1994) *Biochemistry* 33, 5805-5812.
 5. Glaser, PE & Gross, RW " The rapid Plasmylethanolamine-selective fusion of membrane bilayers catalyzed by an isoform of Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH): Discrimination between glycolytic and fusogenic roles of individual GAPDH isoforms." (1995) *Biochemistry* 34, 12193-12203.
 6. Pornnoppadol, C, Friesen, DS, Haussler, TS, Glaser, PEA, & Todd, RD "No difference between platelet serotonin--5-HT(2A) receptors from children with and without ADHD." (1999) *J. Child Adolesc. Psychopharmacol.* 9,27-33.
 7. Glaser PE, Han X, Gross RW. Tubulin is the endogenous inhibitor of the glyceraldehyde-3-phosphate dehydrogenase isoform that catalyzes membrane fusion: Implications for the coordinated regulation of glycolysis and membrane fusion. *Proc. Natl. Acad. Sci.* 2002; 99:14104-9.
 8. Rush CR, Stoops WW, Hays LR, Glaser PEA, Hays LS. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. *J Pharmacol Exp Ther.* 2003 Jul; 306(1):195-204.
 9. Stoops WW, Glaser PEA, and Rush CR. Reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans: a dose-response analysis. *Drug Alcohol Depend.* 2003 Aug 20;71(2):179-86.
 10. Lile JA, Stoops WW, Allen TA, Glaser PEA, Hays LR, and Rush CR. Baclofen does not alter the Reinforcing, subject-related or cardiovascular effects of intranasal cocaine in humans. *Psychopharmacology (Berl).* 2004; 171:441-449.
 11. Rush CR, Stoops WW, Wagner FP, Hays LR, Glaser PEA. Alprazolam Attenuates the Behavioral Effects of d-Amphetamine in Humans. *J Clin Psychopharmacol.* 2004 Aug;24(4):410-420.
 12. Lile JA, Stoops WW, Glaser PEA, Hays LR and Rush CR. Tiagabine does not alter the discriminative-stimulus, reinforcing, subject-rated or cardiovascular effects of cocaine in humans. *Drug and Alcohol Dependence.* 2004; 76: 81-91.
 13. Stoops WW, Fillmore MT, Glaser PEA, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and α -amphetamine in stimulant abusing humans. *J Psychopharmacol.* 2004 Dec;18(4):534-43.
 14. Stoops WW, Lile JA, Fillmore MT, Glaser PEA, and Rush CR. Reinforcing Effects of Methylphenidate: Influence of Dose and Behavioral Demands Following Drug Administration. *Psychopharmacology (Berl).* 2005 Jan;177(3):349-55. Epub 2004 Jul 23.
 15. Glaser PEA, Thomas TC, Joyce BM, Castellanos FX, Gerhardt GA. Differential Effects of Amphetamine Isomers on Dopamine Release in the Rat Striatum and Nucleus Accumbens Core. *Psychopharmacology (Berl).* 2005 Mar;178(2-3):250-8. Epub 2004 Sep 30
 16. Stoops WW, Lile JA, Glaser PEA, and Rush CR. Discriminative-stimulus and self-reported effects of methylphenidate, α -amphetamine, and triazolam in methylphenidate-trained humans. *Exp Clin Psychopharmacol.* 2005 Feb;13(1):56-64.
 17. Rush CR, Higgins ST, Vansickel AR, Stoops WW, Lile JA, Glaser PEA. Methylphenidate increases cigarette smoking. *Psychopharmacology (Berl).* 2005 Oct;181(4):781-9. Epub 2005 Sep 29.
-

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

-
18. Stoops WW, Lile JA, Fillmore MT, Glaser PEA, Rush CR. Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. *Psychopharmacology (Berl)*. 2005 Oct;182(1):186-93. Epub 2005 Sep 29.
 19. Lile JA, Stoops WW, Vansickel AR, Glaser PEA, Hays LR, Rush CR. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. *Neuropsychopharmacology*. 2005 Nov;30(11):2103-14.
 20. Lile JA, Stoops WW, Wagner FP, Glaser PEA, Rush CR. Oxazepam does not modulate the behavioral effects of d-amphetamine in humans. *Pharmacol Biochem Behav*. 2005 Oct;82(2):270-9. Epub 2005 Sep 22.
 21. Glaser PEA, Surgener SP, Grondin R, Gash CR, Palmer M, Castellanos FX, Gerhardt GA. Cerebellar Neurotransmission in Attention-Deficit/Hyperactivity Disorder: Does Dopamine Neurotransmission Occur in the Cerebellar Vermis? *J Neurosci Methods*, 2006 Feb;62-67.
 22. Castellanos FX, Glaser PEA, Gerhardt GA. Towards a neuroscience of attention-deficit/hyperactivity disorder: Fractionating the phenotype. *J Neurosci Methods*. 2006 Feb; 1-3.
 23. Stoops WW, Lile JA, Glaser PEA, Rush CR. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. *Drug Alcohol Depend*. 2006 Sep 15;84(2):206-9.
 24. Lile JA, Stoops WW, Durell TM, Glaser PEA, Rush CR. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. *Exp Clin Psychopharmacol*. 2006 May;14(2):136-47.
 25. Joyce BM, Glaser PEA, Gerhardt GA. Adderall Produces Increased Striatal Dopamine Release and A Prolonged Time Course Compared to Amphetamine Isomers, *Psychopharm*, 2007 Apr;191(3):669-677.
 26. Vansickel AR, Stoops WW, Glaser PEA, Rush CR. A pharmacological analysis of stimulant-induced increases in smoking. *Psychopharmacology (Berl)*. 2007 Apr 20.
 27. Thomas TC, Kruzich PJ, Joyce BM, Gash CR, Suchland K, Surgener SP, Rutherford EC, Grandy DK, Gerhardt GA, Glaser PEA. Dopamine D4 receptor knockout mice exhibit neurochemical changes consistent with decreased dopamine release. *J Neurosci Methods*. 2007 Nov 30;166(2):306-14.
 28. Stoops WW, Vansickel AR, Glaser PEA, Rush CR. The influence of acute varenicline administration on smoking and eating behavior in humans. *Pharmacol Biochem Behav*. 2008 Nov;91(1):165-9. Epub 2008 Jul 13.
 29. Thomas TC, Grandy DK, Gerhardt GA, Glaser PEA. Decreased Dopamine D4 Receptor Expression Increases Extracellular Glutamate and Alters Its Regulation in Mouse Striatum. *Neuropsychopharm*. 2009 Jan;34(2):436-45. Epub 2008 Jun 4. 2008 Jun 4.
 30. Vansickel AR, Poole MM, Stoops WW, Hays KE, Upchurch MB, Glaser PEA, Rush CR. Stimulant-induced changes in smoking and caloric intake: influence of rate of onset. *Pharmacol Biochem Behav*. 2009 Jun;92(4):597-602. Epub 2009 Mar 11.
 31. Al-Janabi I, Arranz MJ, Blakemore AI, Saiz PA, Susce MT, Glaser PEA, Clark D, de Leon J. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. *Psychiatr Genet*. 2009 Dec;19(6):305-11.
-

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

-
32. Stoops WW, Lile JA, Glaser PEA, Hays LR, Rush CR. Intranasal cocaine functions as reinforcer on a progressive ratio schedule in humans. *Eur J Pharmacol.* 2010 Oct 10;644(1-3):101-5. Epub 2010 Jul 16.
 33. Sevak RJ, Stoops WW, Glaser PEA, Hays LR, Rush CR. Reinforcing effects of d-amphetamine: influence of novel ratios on a progressive-ratio schedule. *Behav Pharmacol.* 2010 Oct 12.
 34. Lile JA, Stoops WW, Glaser PEA, Hays LR, Rush CR. Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. *J Psychopharmacol.* 2010 Oct 15.
 35. Durell TM, Adler LA, Liebowitz M, Rubin R, Qiao M, Hollandbeck M, Deldar A, Glaser PEA, Kronenberger W. An 8-Week, Open-Label Extension Period Study of Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder and Comorbid Social Anxiety Disorder. *Journal of ADHD & Related Disorders, Vol. 1, No. 3, p. 36-52.* 2010 Feb.
 36. Miller EM, Gerhardt GA, Glaser PEA. Is ADHD Linked to a Dopamine Signaling Deficit? *Cell Science* 2010. 27(2). ISSN 1742-8130.
 37. Rush CR, Stoops WW, Lile JA, Glaser PEA, Hays LR. Subjective and physiological effects of acute intranasal methamphetamine during D: -amphetamine maintenance. *Psychopharmacology (Berl).* 2010 Nov 12.
 38. Stoops WW, Poole MM, Vansickel AR, Hays KA, Glaser PEA, Rush CR. Methylphenidate Increases Choice of Cigarettes Over Money. *Nicotine Tob Res. Volume 13, Number 1, January 2011, 29–33.*
 39. Munro J, Skrobot O, Sanyoura M, Kay V, Susce MT, Glaser PEA, de Leon J, Blakemore AIF, Arranz MJ. Relaxin polymorphisms associated with metabolic disturbance in patients treated with antipsychotics. *Journal of Psychopharmacology, 2011 Jun 21.*
 40. Sevak RJ, Vansickel AR, Stoops WW, Glaser PEA, Hays LR, Rush CR. Discriminative-stimulus, subject-rated and physiological effects of methamphetamine in humans pretreated with aripiprazole. *Journal of Clinical Psychopharmacology, 2011 Aug;31(4):470-80.*
 41. Hascup KN, Hascup ER, Stephens ML, Glaser PEA, Yoshitake T, Mathé AA, Gerhardt GA, Kehr J. Resting Glutamate Levels and Rapid Glutamate Transients in the Prefrontal Cortex of the Flinders Sensitive Line Rat: A Genetic Rodent Model of Depression, *Neuropsychopharmacology, 2011 Jul;36(8):1769-77.*
 42. Vansickel AR, Stoops WW, Glaser PEA, Poole MM, Rush CR, Methylphenidate Increases Cigarette Smoking in Participants with ADHD, *Psychopharmacology, 2011 May 18.*
 43. Lile JA, Stoops WW, Glaser PEA, Hays LR, Rush CR. Physiological and subjective effects of acute intranasal methamphetamine during extended-release alprazolam maintenance. *Drug Alcohol Depend.* 2011 Jul 5.
 44. Rush CR, Stoops WW, Lile JA, Glaser PEA, Hays LR. Physiological and subjective effects of acute intranasal methamphetamine during atomoxetine maintenance. *Pharmacol Biochem Behav.* 2011 Nov; 100(1):40-7.
 45. Stoops WW, Lile JA, Glaser PEA, Hays LR, Rush CR. Alternative reinforcer response cost impacts cocaine choice in humans. *Prog Neuropsychopharmacol Biol Psychiatry.* 2012 Jan 10;36(1):189-93.
 46. Stoops WW, Lile JA, Glaser PEA, Hays LR, Rush CR. Influence of acute bupropion pre-treatment on the effects of intranasal cocaine. *Addiction.* 2012 Jun;107(6):1140-7.
-

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

47. Miller EM, Pomerleau F, Huettl P, Russell VA, Gerhardt GA, Glaser PEA. The spontaneously hypertensive and Wistar Kyoto rat models of ADHD exhibit sub-regional differences in dopamine release and uptake in the striatum and nucleus accumbens. *Neuropharmacology*. 2012 Sep 1;63(8):1327-1334.
 48. Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PEA, Rubin RL, Pigott TA, Sarkis EH, Fox BK. Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder in Young Adults With Assessment of Functional Outcomes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *J Clin Psychopharmacol*. 2013 Feb;33(1):45-54.
 49. Stoops WW, Glaser PEA, and Rush CR. Miotic and Subject-Rated Effects of Therapeutic Doses of Tapentadol, Tramadol and Hydromorphone in Occasional Opioid Users. *Psychopharmacology*. 2013 Jul;228(2):255-262.
 50. Miller EM, Pomerleau F, Huettl P, Gerhardt GA, Glaser PE. Aberrant glutamate signaling in the prefrontal cortex and striatum of the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder. *Psychopharmacology (Berl)*. 2014 Feb 28.
 51. Leuchter AF, McGough JJ, Korb AS, Hunter AM, Glaser PE, Deldar A, Durell TM, Cook IA. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project. *J Psychiatr Res*. 2014 Jul;54:11-8.
 52. Pike E, Stoops WW, Hays LR, Glaser PE, Rush CR. Methamphetamine Self-administration in Humans During D-Amphetamine Maintenance. *J Clin Psychopharmacol*. 2014 Aug 22.
 53. Stoops WW, Pike E, Hays LR, Glaser PE, Rush CR. Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine. *Pharmacol Biochem Behav*. 2015 Feb;129:45-50.
 54. Joseph JE, Zhu X, Gundran A, Davies F, Clark JD, Ruble L, Glaser PE, Bhatt RS. Typical and atypical neurodevelopment for face specialization: an fMRI study. *J Autism Dev Disord*. 2015 Jun;45(6):1725-41.
 55. Miller EM, Quintero JE, Pomerleau F, Huettl P, Gerhardt GA, Glaser PE. Simultaneous glutamate recordings in the frontal cortex network with multisite biomorphic microelectrodes: New tools for ADHD research. *J Neurosci Methods*. 2015 Aug 30;252:75-9.
 56. Marks KR, Lile JA, Stoops WW, Glaser PE, Hays LR, Rush CR. Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine. *J Clin Psychopharmacol*. 2016 Jun;36(3):213-21.
 57. Lile JA, Stoops WW, Rush CR, Negus SS, Glaser PE, Hatton KW, Hays LR. Development of a translational model to screen medications for cocaine use disorder II: Choice between intravenous cocaine and money in humans. *Drug Alcohol Depend*. 2016 Aug 1;165:111-9.
 58. Atkinson, DL, Glaser, PE, Weigle, PE. Can a Behavior Be Addictive? How Can the Field of Substance Use Inform Treatment of Problematic Video Gaming and Internet Use? *Clin. Perspectives*. 2018 Oct 1;57:S71.
 59. Miller EM, Quintero JE, Pomerleau F, Huettl P, Gerhardt GA, Glaser PE. Chronic Methylphenidate Alters Tonic and Phasic Glutamate Signaling in the Frontal Cortex of a Freely-Moving Rat Model of ADHD. *Neurochem Res*. 2019 Jan;44(1):89-101
 60. Hagler DJ Jr., Glaser PE et al. Image processing and analysis methods for the Adolescent Brain Cognitive Development Study. *Neuroimage* 2019 Aug 12:116091.
-

Paul E.A. Glaser, M.D., Ph.D.

Professor, Washington University in St. Louis

660 S. Euclid Ave, Campus Box 8504 • St. Louis MO 63110

(314) 747-9402 (office)

(314) 747-6777 (fax)

e-mail: peglaser@wustl.edu

61. Mintz CM, Presnall NJ, Sahrman JM, Borodovsky JT, Glaser PEA, Bierut LJ, Gruzca RA. Age disparities in six-month treatment retention for opioid use disorder. *Drug Alcohol Depend.* 2020 Jun.
62. Mattingly GW, Wilson J, Ugarte L, Glaser PE. Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions. *CNS Spectr.* 2020 Feb 14:1-20.
63. Herting MM, Uban KA, Glaser PE, et al. Correspondence Between Perceived Pubertal Development and Hormone Levels in 9-10 Year-Olds From the Adolescent Brain Cognitive Development Study. *Front Endocrinol (Lausanne).* 2021 Feb 18
64. Li Y, Thompson WK, Reuter C, Glaser PE, et al. Rates of Incidental Findings in Brain Magnetic Resonance Imaging in Children. *JAMA Neurol.* 2021 Mar 22.
65. Chaarani B, Hahn S, Glaser P, et al. Baseline brain function in the preadolescents of the ABCD Study. *Nat Neurosci.* 2021 Aug.
66. Xu KY, Mintz CM, Borodovsky JT, Glaser PEA, Bierut LJ, Gruzca RA. Prevalence of Kratom Use and Co-Occurring Substance Use Disorders in the United States. *Prim Care Companion CNS Disord.* 2021 Aug 5.
67. Lisdahl KM, Tapert S, Glaser PEA, et al. Substance use patterns in 9-10 year olds: Baseline findings from the adolescent brain cognitive development (ABCD) study. *Drug and Alcohol Dependence*, Volume 227, 2021 October 1.
68. Mattingly GW, Glaser PEA, et al. Expert Consensus Guidelines for Telepsychiatry and Attention Deficit Hyperactivity Disorder. *CNS Spectrums*, 2023, in submission.

Book Chapters

1. Glaser PEA, Castellanos FX, Margulies, DS. The Neuropharmacology of Attention-Deficit/Hyperactivity Disorder, in the "Handbook of Contemporary Neuropharmacology". 2007 March.
 2. Rush CR, Vansickel AR, Stoops WW, and Glaser PEA. Methylphenidate for the Treatment of ADHD: Clinical Efficacy, Abuse Potential and Consequences of Use. In: Pates, R. (ed), *Interventions for Amphetamines*. Blackwells Publishers, Oxford, 2007 Oct.
 3. Dwoskin LP, Glaser PEA, and Bardo MT. Methamphetamine; in "Addiction Medicine: Science and Practice" Bankole A. Johnson Publisher: Springer Science + Business Media, LLC New York 2010 Dec.
 4. Glaser PEA & Gerhardt GA. The Neuropsychopharmacology of Stimulants: Dopamine and ADHD; in *Attention Deficit Hyperactivity Disorder / Book 1*, InTech, 2012 Feb.
 5. Miller EM, Thomas TC, Gerhardt GA, and Glaser PEA. Dopamine and Glutamate Interactions in ADHD: Implications for the Future Neuropharmacology of ADHD in *Attention Deficit Hyperactivity Disorder / Book 2*, InTech, 2013 Feb.
 6. Batten SR, Gerhardt GA, Glaser PEA. Should We Be Excited About Glutamate Dysregulation in the Etiology of ADHD? A Review of the Data in "Modulators of Glutamatergic Signaling as Potential Treatments of Neuropsychiatric Disorders", Nova Science, 2015 Sept.
-